IBRX Stock Sees Sharp UAE-Driven Jump Followed By Early August Pullback

On July 29, UAE regulators approved ImmunityBio's cancer drug ANKTIVA for two indications.

The approval sparked a rally in ImmunityBio's stock (IBRX) the next day.

The stock experienced a sharp pullback in early August.